23.1 C
Delhi
Tuesday, November 29, 2022

High Court Opening Its Doors to Public on Non-Argument Days

https://ift.tt/hrLjdQG Supreme Court is making a fuller...

Leading Media Outlets Urge US to End Prosecution of Julian Assange

https://ift.tt/hrLjdQG United States should end its prosecution...

Biden Asks Congress to Avert Rail Strike, Warning of Dire Economic Impact

https://ift.tt/fkhrJ6M. President Joe Biden on Monday called...

Military medics tout new vaccine to end Covid-19 pandemic

A candidate vaccine that uses a novel platform and may be good enough to deal with existing and emerging variants of SARS-CoV-2 viruses, will reportedly be announced soon by researchers at the Walter Reed Army Institute in the US.

The unveiling may come “within weeks,” according to Dr. Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, who was interviewed by Defense One. According to the military publication, the candidate vaccine may offer a single-shot, wide-scale immunity from diseases caused by human coronaviruses, including from future mutations.

Read more

US President Joe Biden speaks about the country's fight against Covid-19 at the White House, December 21, 2021.
Biden claims ‘almost all’ Covid victims in America were unvaccinated

The formula uses a novel Spike Ferritin Nanoparticle (SpFN) platform. Ferritins are natural proteins shaped like globular cages that are normally used by an organism to store iron. Its self-assembly properties have made it an interesting tool for nanofabrication applications. 

ADVERTISEMENT

In the case of vaccination, the protein’s 24 subunits can be fitted with protein spikes similar to those that viruses use to attach to living cells before infecting them. Such nanoparticles may be injected to train the immune system to fight against real viruses. With various kinds of spike proteins included in the same vaccine, it can immunize against a wide range of viruses, past and future, the researchers hope.

Modjarrad’s team says it has good expectations about the efficacy and other properties of their SpFN vaccine-in-waiting, after conducting clinical trials with animals. Their latest publication in Science Translational Medicine details experiments they conducted on rhesus macaques. A separate, Phase 1 human trial has been underway since April.

The challenge with the human trials, Modjarrad told Defense One, was and remains finding people who are still unvaccinated and never caught Covid-19 for the studies to be accurate. He added that his team also wants to evaluate their product “in the real-world setting” with people who were vaccinated or who’ve recovered from the disease.

https://ift.tt/33EvGFA 22, 2021 at 02:56PM
from RT – Daily news

ADVERTISEMENT

Support Us

Secured by Paypal

Related Stories

Check out other tags:

Most Popular Articles